{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:33:43Z","timestamp":1785148423190,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"1. University of Virginia Ivy Foundation Grant 2. University of Virginia\u2019s Global Infectious Diseases Institute 3. Manning Fund"},{"name":"University of Virginia Global Infectious Diseases Institute University of Virginia Manning Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.<\/jats:p>","DOI":"10.1038\/s41541-021-00399-0","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T11:06:20Z","timestamp":1637233580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant"],"prefix":"10.1038","volume":"6","author":[{"given":"Mayuresh M.","family":"Abhyankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5549-2562","authenticated-orcid":false,"given":"Barbara J.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-3299","authenticated-orcid":false,"given":"Jeffrey M.","family":"Sturek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Brovero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Brett","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Sengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal M.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeh","family":"Agah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-1829","authenticated-orcid":false,"given":"Anna","family":"Pom\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-8103","authenticated-orcid":false,"given":"Peter M.","family":"Kasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Tomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4644-2619","authenticated-orcid":false,"given":"Christopher B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"William A.","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"399_CR1","unstructured":"Global Health Estimates: Life expectancy and leading causes of death and disability. https:\/\/www.who.int\/data\/maternal-newborn-child-adolescent-ageing\/advisory-groups\/gama\/activities-of-gama."},{"key":"399_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"399_CR3","first-page":"e240","volume":"2","author":"WN Chia","year":"2021","unstructured":"Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet.Microbe 2, e240\u2013e249 (2021).","journal-title":"Microbe"},{"key":"399_CR4","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(20)30275-7","volume":"2","author":"JJ Manson","year":"2020","unstructured":"Manson, J. J. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2, e594\u2013e602 (2020).","journal-title":"Lancet Rheumatol."},{"key":"399_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20139-7","volume":"11","author":"N Desai","year":"2020","unstructured":"Desai, N. et al. Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nat. Commun. 11, 6319 (2020).","journal-title":"Nat. Commun."},{"key":"399_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","volume":"21","author":"JR Teijaro","year":"2021","unstructured":"Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195\u2013197 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"399_CR7","unstructured":"COVID-19 vaccine tracker and landscape. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"399_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615\u2013632 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"399_CR9","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","volume":"21","author":"SH Hodgson","year":"2021","unstructured":"Hodgson, S. H. et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. 21, e26\u2013e35 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"399_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","volume":"594","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam, P. S. et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 594, 253\u2013258 (2021).","journal-title":"Nature"},{"key":"399_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/pharmaceutics13020142","volume":"13","author":"M Luchner","year":"2021","unstructured":"Luchner, M., Reinke, S. & Milicic, A. TLR agonists as vaccine adjuvants targeting cancer and infectious diseases. Pharmaceutics 13, 142 (2021).","journal-title":"Pharmaceutics"},{"key":"399_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.vaccine.2016.12.057","volume":"35","author":"MM Abhyankar","year":"2017","unstructured":"Abhyankar, M. M. et al. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine 35, 916\u2013922 (2017).","journal-title":"Vaccine"},{"key":"399_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0060-x","volume":"3","author":"MM Abhyankar","year":"2018","unstructured":"Abhyankar, M. M. et al. Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica. NPJ Vaccines 3, 22 (2018).","journal-title":"NPJ Vaccines"},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4269\/ajtmh.20-0762","volume":"103","author":"GB Moreau","year":"2020","unstructured":"Moreau, G. B. et al. Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. Am. J. Trop. Med Hyg. 103, 1215\u20131219 (2020).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"399_CR15","doi-asserted-by":"publisher","first-page":"683157","DOI":"10.3389\/fimmu.2021.683157","volume":"12","author":"MM Abhyankar","year":"2021","unstructured":"Abhyankar, M. M. et al. Optimizing a multi-component intranasal entamoeba histolytica vaccine formulation using a design of experiments strategy. Front. Immunol 12, 683157 (2021).","journal-title":"Front. Immunol"},{"key":"399_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"399_CR17","doi-asserted-by":"publisher","first-page":"eabe5511","DOI":"10.1126\/sciimmunol.abe5511","volume":"5","author":"B Isho","year":"2020","unstructured":"Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol 5, eabe5511 (2020).","journal-title":"Sci. Immunol"},{"key":"399_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","volume":"53","author":"A Sariol","year":"2020","unstructured":"Sariol, A. & Perlman, S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity 53, 248\u2013263 (2020).","journal-title":"Immunity"},{"key":"399_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","volume":"239","author":"MS Duthie","year":"2011","unstructured":"Duthie, M. S., Windish, H. P., Fox, C. B. & Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239, 178\u2013196 (2011).","journal-title":"Immunol. Rev."},{"key":"399_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3389\/fimmu.2020.01112","volume":"11","author":"JT Martinsen","year":"2020","unstructured":"Martinsen, J. T., Gunst, J. D., H\u00f8jen, J. F., Tolstrup, M. & S\u00f8gaard, O. S. The use of toll-like receptor agonists in HIV-1 cure strategies. Front Immunol. 11, 1112 (2020).","journal-title":"Front Immunol."},{"key":"399_CR21","doi-asserted-by":"publisher","first-page":"624483","DOI":"10.3389\/fcimb.2021.624483","volume":"11","author":"FJ Gil-Etayo","year":"2021","unstructured":"Gil-Etayo, F. J. et al. T-helper cell subset response is a determining factor in COVID-19 progression. Front Cell Infect. Microbiol 11, 624483 (2021).","journal-title":"Front Cell Infect. Microbiol"},{"key":"399_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18058-8","volume":"11","author":"M Ejemel","year":"2020","unstructured":"Ejemel, M. et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat. Commun. 11, 4198 (2020).","journal-title":"Nat. Commun."},{"key":"399_CR23","doi-asserted-by":"publisher","first-page":"eabf1555","DOI":"10.1126\/scitranslmed.abf1555","volume":"13","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA.Sci. Transl. Med. 13, eabf1555 (2021).","journal-title":"Sci. Transl. Med."},{"key":"399_CR24","doi-asserted-by":"publisher","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","volume":"13","author":"D Sterlin","year":"2021","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).","journal-title":"Sci. Transl. Med."},{"key":"399_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/v12080862","volume":"12","author":"T Wang","year":"2020","unstructured":"Wang, T., Wei, F. & Liu, J. Emerging role of mucosal vaccine in preventing infection with Avian influenza a viruses. Viruses 12, 862 (2020).","journal-title":"Viruses"},{"key":"399_CR26","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.vaccine.2014.02.004","volume":"32","author":"C Ma","year":"2014","unstructured":"Ma, C. et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 32, 2100\u20132108 (2014).","journal-title":"Vaccine"},{"key":"399_CR27","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 183, 1735 (2020).","journal-title":"Cell"},{"key":"399_CR28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"399_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1165\/rcmb.2009-0210ST","volume":"44","author":"G Matute-Bello","year":"2011","unstructured":"Matute-Bello, G. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 44, 725\u2013738 (2011).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"399_CR30","doi-asserted-by":"crossref","unstructured":"Sengar, A., Bondalapati, S. T. & Kasson, P. Single-virus fusion measurements yield an opportunistic model for SARS-CoV-2 fusion. bioRxiv 2021.05.04.442634 (2021).","DOI":"10.1101\/2021.05.04.442634"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00399-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:21:32Z","timestamp":1670023292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00399-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00399-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"10 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.A.P. is a consultant for TechLab, Inc. and in addition receives royalties for amebiasis diagnostics that are donated in their entirety to the American Society of Tropical Medicine and Hygiene. M.A.T. is an employee of 3\u2009M and 3M-052 is an asset of 3\u2009M\u2019s. C.B.F. is an employee of IDRI, which owns assets including patents and patent applications involving formulations of GLA and 3M-052 including what is represented in this manuscript. All other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}